Christof David Vinnemeier1, Johanna Fischer-Herr1, Seetha Meyer2, Katja Liebig2, Wiebke Theeß3, Gerd-Dieter Burchard1, Jakob P Cramer1. 1. University Medical Center Hamburg-Eppendorf; I. Department for Internal Medicine; Section Tropical Medicine; Hamburg, Germany; Bernhard Nocht Center for Clinical Trials (BNCCT); Hamburg, Germany. 2. Novartis Vaccines and Diagnostics GmbH; Marburg, Germany. 3. Bernhard Nocht Center for Clinical Trials (BNCCT); Hamburg, Germany.
Abstract
BACKGROUND: The present study aimed to evaluate immunogenicity and safety of the 2012/2013 seasonal influenza vaccine (Optaflu(®)) after the World Health Organization recommended two new strains for the composition. RESULTS: Twenty-one days post-vaccination geometric mean titers (GMTs) against A(H1N1), A(H3N2) and the B strain were 528, 935, and 201 for adults and 272, 681, and 101 for elderly subjects, respectively. The proportion of subjects with a HI titer of ≥ 40 against the three strains A(H1N1), A(H3N2) and B was 98%, 100%, and 98% in adults and 100%, 100%, and 85% in elderly subjects, respectively. Optaflu(®) met the CHMP criteria of the Committee for Medicinal Products for Human Use (CPMP/BWP/214/96). Pre-vaccination titers indicated seroprotection against the A(H1N1), the A(H3N2) and the B strain in 56%, 86%, and 54% of the adults and in 61%, 85%, and 40% of the elderly with highest titers against the A(H3N2) strain. In the safety analysis injection site pain (37%) and myalgia (31%) were the most common local and systemic reactions. No serious adverse events were recorded. CONCLUSION: The 2012/2013 seasonal influenza vaccine Optaflu(®) showed good immunogenicity and an acceptable safety profile in both adults and elderly. METHODS: In this trial, 126 subjects (63 adults ≥18 to ≤60 y, 63 elderly ≥61 y) were vaccinated with a single dose Optaflu(®) containing each of the three virus strains recommended for the 2012/2013 season (A/California/7/2009(H1N1)-like strain, A/Victoria/361/2011(H3N2)-like strain, and B/Wisconsin/1/2010-like strain). Immunogenicity was assessed by hemagglutinin inhibition (HI) and single radial hemolysis (SRH) assays on day 22, the safety profile was investigated throughout the whole study period.
BACKGROUND: The present study aimed to evaluate immunogenicity and safety of the 2012/2013 seasonal influenza vaccine (Optaflu(®)) after the World Health Organization recommended two new strains for the composition. RESULTS: Twenty-one days post-vaccination geometric mean titers (GMTs) against A(H1N1), A(H3N2) and the B strain were 528, 935, and 201 for adults and 272, 681, and 101 for elderly subjects, respectively. The proportion of subjects with a HI titer of ≥ 40 against the three strains A(H1N1), A(H3N2) and B was 98%, 100%, and 98% in adults and 100%, 100%, and 85% in elderly subjects, respectively. Optaflu(®) met the CHMP criteria of the Committee for Medicinal Products for Human Use (CPMP/BWP/214/96). Pre-vaccination titers indicated seroprotection against the A(H1N1), the A(H3N2) and the B strain in 56%, 86%, and 54% of the adults and in 61%, 85%, and 40% of the elderly with highest titers against the A(H3N2) strain. In the safety analysis injection site pain (37%) and myalgia (31%) were the most common local and systemic reactions. No serious adverse events were recorded. CONCLUSION: The 2012/2013 seasonal influenza vaccine Optaflu(®) showed good immunogenicity and an acceptable safety profile in both adults and elderly. METHODS: In this trial, 126 subjects (63 adults ≥18 to ≤60 y, 63 elderly ≥61 y) were vaccinated with a single dose Optaflu(®) containing each of the three virus strains recommended for the 2012/2013 season (A/California/7/2009(H1N1)-like strain, A/Victoria/361/2011(H3N2)-like strain, and B/Wisconsin/1/2010-like strain). Immunogenicity was assessed by hemagglutinin inhibition (HI) and single radial hemolysis (SRH) assays on day 22, the safety profile was investigated throughout the whole study period.
Authors: Katherine A Poehling; Kathryn M Edwards; Geoffrey A Weinberg; Peter Szilagyi; Mary Allen Staat; Marika K Iwane; Carolyn B Bridges; Carlos G Grijalva; Yuwei Zhu; David I Bernstein; Guillermo Herrera; Dean Erdman; Caroline B Hall; Ranee Seither; Marie R Griffin Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: C B Bridges; W W Thompson; M I Meltzer; G R Reeve; W J Talamonti; N J Cox; H A Lilac; H Hall; A Klimov; K Fukuda Journal: JAMA Date: 2000-10-04 Impact factor: 56.272
Authors: W A Keitel; R B Couch; T R Cate; K R Hess; B Baxter; J M Quarles; R L Atmar; H R Six Journal: J Clin Microbiol Date: 1994-10 Impact factor: 5.948
Authors: Donald Y M Leung; Brett Jepson; Lisa A Beck; Jon M Hanifin; Lynda C Schneider; Amy S Paller; Katherine Monti; Gloria David; Jennifer Canniff; Margarita Gomez Lorenzo; Adriana Weinberg Journal: J Allergy Clin Immunol Date: 2017-02-13 Impact factor: 10.793
Authors: Stephan Bart; Kevin Cannon; Darrell Herrington; Richard Mills; Eduardo Forleo-Neto; Kelly Lindert; Ahmed Abdul Mateen Journal: Hum Vaccin Immunother Date: 2016-06-20 Impact factor: 3.452
Authors: Surender Khurana; Megan Hahn; Elizabeth M Coyle; Lisa R King; Tsai-Lien Lin; John Treanor; Andrea Sant; Hana Golding Journal: Nat Commun Date: 2019-07-26 Impact factor: 14.919